We are pleased to announce a new partnership between Pfizer, Ataxia UK and three academic institutions on a new friedreich’s ataxia drug discovery project
A new drug discovery project, funded by the pharmaceutical company Pfizer and Ataxia UK, will involve researchers from UCL, Imperial College London and Oxford University. The aim of the collaboration is to find a new drug therapy for people with Friedreich’s ataxia.
A phase 3 study to identify the safety, efficacy and tolerability of the drug ACTIMMUNE® (Interferon gamma-1b) on people with FA has been initiated.
Take a look at what Dr Blabanov had to say about drug development at our conference. He is a scientific administrator for the EMA, who evaluate medicinal products in Europe.